Single gene contributions: Genetic variants of peroxisome proliferator-activated receptor (isoforms α, β/δ and γ) and mechanisms of dyslipidemias

Current Opinion in Lipidology

Volumn 19, Issue 2, 2008, Pages 106-112

  Yong, Eu Leong ^a   Li, Jun ^a   Liu, Mei Hui ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Dyslipidemia; Genetic variants; Peroxisome proliferator activated receptor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENERGY YIELD; FATTY ACID OXIDATION; GENE EXPRESSION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INSULIN RESISTANCE; LIPID TRANSPORT; LIPODYSTROPHY; MATURITY ONSET DIABETES MELLITUS; MITOCHONDRIAL GENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

DYSLIPIDEMIAS; GENOTYPE; HUMANS; MUTATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHENOTYPE; PROTEIN ISOFORMS;

EID: 41649120952     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f64542     Document Type: Review

References (69)

1. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-1345. This genome-wide study identified loci for genetic susceptibility to type 2 diabetes.
2. Germain P, Staels B, Dacquet C, et al. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58:685-704.
3. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 2004; 61:393-416.
4. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116:581-589. This is a recent review by the discoverers of several key mutations causing PPARγ ligand resistance syndromes.
5. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-2422.
6. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-883.
7. Semple RK, Meirhaeghe A, Vidal-Puig AJ, et al. A dominant negative human peroxisome proliferator-activated receptor (PPAR)α is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology 2005; 146:1871-1882.
8. Gray SL, Nora ED, Grosse J, et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 2006; 55:2669-2677. Recreation of the FPLD phenotype only in the leptin-deficient ob/ob mouse model indicates that the P465L mutation becomes physiologically relevant only when it is challenged by extreme changes in energy balance.
9. Gray SL, Dalla Nora E, Backlund EC, et al. Decreased brown adipocyte recruitment and thermogenic capacity in mice with impaired peroxisome proliferator-activated receptor (P465L PPARg) function. Endocrinology 2006; 147:5708-5714. Function of the PPARg in regulating adipose tissue types is described.
10. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 2006; 4:303-311. This report describes a mechanism whereby mutants in the PPARγ DBD and LBD can interfere with transcription through 'squelching' by sequestration of coregulators.
11. Li G, Leff T. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes. Mol Endocrinol 2007; 21:857-864. The authors describe a new mechanism of pathogenesis.
12. Monajemi H, Zhang L, Li G, et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 2007; 92:1606-1612.
13. Ludtke A, Buettner J, Wu W, et al. Peroxisome proliferator- activated receptor-gamma C190S mutation causes partial lipodystrophy. J Clin Endocrinol Metab 2007; 92:2248-2255.
14. Francis GA, Li G, Casey R, et al. Peroxisomal proliferator- activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 2006; 7:3.
15. Ludtke A, Buettner J, Schmidt HH, Worman HJ. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand. J Med Genet 2007; 44:e88.
16. Jeninga EH, van Beekum O, van Dijk AD, et al. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. Mol Endocrinol 2007; 21:1049-1065.
17. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with prediabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29:2489-2497. This is a good review of the dyslipidemias associated with the common PPARγ variant (P12A).
18. Li L, Cheng LX, Nsenga R, et al. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 2006; 29:300-304.
19. Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci Lett 2006; 410:141-145.
20. Stefanski A, Majkowska L, Ciechanowicz A, et al. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J Hum Hypertens 2006; 20:684-692.
21. Cardona F, Morcillo S, Gonzalo-Marin M, et al. Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin Chem 2006; 52:1920-1925.
22. Hansen L, Ekstrom CT, Tabanera YPR, et al. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91:3446-3450.
23. Meirhaeghe A, Boreham CA, Murray LJ, et al. A possible role for the PPARG Pro12Ala polymorphism in preterm birth. Diabetes 2007; 56:494-498. A fascinating hypothesis is proposed that suggests a role for PPARγ in regulating onset of labor.
24. Scaglioni S, Verduci E, Salvioni M, et al. PPAR-gamma2 Pro12Ala variant, insulin resistance and plasma long-chain polyunsaturated fatty acids in childhood obesity. Pediatr Res 2006; 60:485-489.
25. Pfab T, Poralla C, Richter CM, et al. Fetal and maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala does not influence birth weight. Obesity (Silver Spring) 2006; 14:1880-1885.
26. de Rooij SR, Painter RC, Phillips DI, et al. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care 2006; 29:1052-1057. The authors make the intriguing suggestion that effects of PPARg can be unmasked by extreme prenatal deprivation.
27. Wang Y, Wu X, Cao Y, et al. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril 2006; 85:1536-1540.
28. Antoine HJ, Pall M, Trader BC, et al. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril 2007; 87:862-869.
29. Ludovico O, Pellegrini F, Di Paola R, et al. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 2007; 15:1076-1081. This is a recent meta-analysis of more than 40 000 individuals.
30. Jaziri R, Lobbens S, Aubert R, et al. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006; 55:1157-1162.
31. Chen TJ, Ji CY, Zheng XY, Hu YH. Association of beta3 adrenergic receptor and peroxisome proliferator-activated receptor gamma 2 polymorphisms with insulin sensitivity: a twin study. Biomed Environ Sci 2007; 20:99-105.
32. Goyenechea E, Parra MD, Martinez JA. Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome- proliferator-activated-receptor-gamma2 gene polymorphisms. Br J Nutr 2006; 96:965-972.
33. Adamo KB, Dent R, Langefeld CD, et al. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity (Silver Spring) 2007; 15:1068-1075.
34. Tanko LB, Siddiq A, Lecoeur C, et al. ACDC/adiponectin and PPAR-gamma gene polymorphisms: implications for features of obesity. Obes Res 2005; 13:2113-2121.
35. Nassar BA, Rockwood K, Kirkland SA, et al. Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. Clin Biochem 2006; 39:109-114.
36. Nelson TL, Fingerlin TE, Moss LK, et al. Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado. Metabolism 2007; 56:388-393.
37. Cecil JE, Watt P, Palmer CN, Hetherington M. Energy balance and food intake: the role of PPARgamma gene polymorphisms. Physiol Behav 2006; 88:227-233.
38. Rittig K, Thamer C, Machicao F, et al. The Pro12Ala polymorphism in PPARG2 increases the effectiveness of primary prevention of cardiovascular disease by a lifestyle intervention. Diabetologia 2007; 50:1345-1347.
39. Soriguer F, Morcillo S, Cardona F, et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006; 136:2325-2330.
40. Ylonen SK, Salminen I, Lyssenko V, et al. The Pro12Ala polymorphism of the PPAR-gamma2 gene affects associations of fish intake and marine n-3 fatty acids with glucose metabolism. Eur J Clin Nutr 2007 [Epub ahead of print].
41. Tschritter O, Fritsche A, Stefan N, et al. Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala. Metabolism 2003; 52:778-783.
42. Naito H, Yamanoshita O, Kamijima M, et al. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 2006; 16:569-577.
43. Uthurralt J, Gordish-Dressman H, Bradbury M, et al. PPAR alpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet 2007; 8:55. This study indicated a much greater effect of the 162V allele, particularly in triglyceride levels, than was previously reported in older and less healthy populations.
44. Sparso T, Hussain MS, Andersen G, et al. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab 2007; 90:205-209. This is the first large study to examine the association of the L162V variant with risk for obesity or type 2 diabetes.
45. Tanaka T, Ordovas JM, Delgado-Lista J, et al. Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. J Lipid Res 2007; 48:1402-1408.
46. Manresa JM, Zamora A, Tomas M, et al. Relationship of classical and nonclassical risk factors with genetic variants relevant to coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006; 13:738-744.
47. Tai ES, Collins D, Robins SJ, et al. The L162V polymorphism at the peroxisome proliferator-activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006; 187:153-160.
48. Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2006; 55:2148-2152. This article showed for the first time that single nucleotide polymorphisms of PPARD, together with the Gly482Ser polymorphism of PGC-1A and the P12A genotype of PPARG2, are associated with risk for type 2 diabetes.
49. Tai ES, Corella D, Demissie S, et al. Polyunsaturated fatty acids interact with the PPARA- L162VpolymorphismtoaffectplasmatriglycerideandapolipoproteinCIII concentrations in the Framingham Heart Study. J Nutr 2005; 135:397-403.
50. Paradis AM, Fontaine-Bisson B, Bosse Y, et al. The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr 2005; 81:523-530.
51. Chan E, Tan CS, Deurenberg-Yap M, et al. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 2006; 187:309-315. This is the first study to suggest that the V227A variant may determine the lipid response to changes in PUFA intake.
52. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, et al. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARa) gene is associated with variations in serum lipid levels. J Med Genet 2002; 39:189-191.
53. Hara M, Wang X, Paz VP, et al. Identification of three missense mutations in the peroxisome proliferator-activated receptor alpha gene in Japanese subjects with maturity-onset diabetes of the young. J Hum Genet 2001; 46:285-288.
54. Foucher C, Rattier S, Flavell DM, et al. Response to micronized fenofibrate treatment is associated with the peroxisome proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004; 14:823-829.
55. Doney AS, Fischer B, Lee SP, et al. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recept 2005; 3:4.
56. Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease. Acta Cardiol 2007; 62:233-238.
57. Flavell DM, Ireland H, Stephens JW, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005; 54:582-586.
58. Grarup N, Albrechtsen A, Ek J, et al. Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 2007; 50:1201-1208.
59. Aberle J, Hopfer I, Beil FU, Seedorf U. Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 2006; 3:108-111.
60. Hautala AJ, Leon AS, Skinner JS, et al. Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study. Am J Physiol Heart Circ Physiol 2007; 292:H2498-H2505.
61. Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 2007; 31:411-417.
62. Stefan N, Thamer C, Staiger H, et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007; 92:1827-1833.
63. Aberle J, Hopfer I, Beil FU, Seedorf U. Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 2006; 30:1709-1713.
64. Vanttinen M, Nuutila P, Kuulasmaa T, et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene is associated with skeletal muscle glucose uptake. Diabetes 2005; 54:3587-3591.
65. Shin HD, Park BL, Kim LH, et al. Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 2004; 53:847-851.
66. Hu C, Jia W, Fang Q, et al. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet Med 2006; 23:1307-1312.
67. Holzapfel J, Heun R, Lutjohann D, et al. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. Neurosci Lett 2006; 408:57-61.
68. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007; 56:1181-1186.
69. Shen P, Liu MH, Ng TY, et al. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARα, PPARγ, and adipocyte differentiation in vitro. J Nutr 2006; 136:899-905. This paper provides a description of flavonoids from plants and other nutritional sources that modulate PPAR function.